Evidence map›Paper›PMID 39881397›Full record

ArticleAddiction science & clinical practice2025

mHealth Incentivized Adherence Plus Patient Navigation (MIAPP): protocol for a pilot randomized controlled trial to improve linkage and retention on buprenorphine for hospitalized patients with methamphetamine use and opioid use disorder.

Elenore P Bhatraju, Devin N Kennedy, Alexander J Gojic, Matthew Iles-Shih, Joseph O Merrill, Jeffrey H Samet, Kevin A Hallgren, Judith I Tsui

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in Addiction science & clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06027814 (Patient Navigator Plus Remote mHealth Adherence Support With Incentives to Improve Linkage and Retention Among Hospitalized Patients With Opioid and Methamphetamine Use Who Initiate Buprenorphine), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06027814 naactive not recruitingnot on this map

Patient Navigator Plus Remote mHealth Adherence Support With Incentives to Improve Linkage and Retention Among Hospitalized Patients With Opioid and Methamphetamine Use Who Initiate Buprenorphine

TypeinterventionalSponsorUniversity of WashingtonRan2024 to 2026Enrolled40ConditionsOpioid Use Disorder, Medication Adherence, Polysubstance Drug Use (Indiscriminate Drug Use), Methamphetamine-dependenceArmsPatient Navigation and mHealth (PN+mHealth)
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elenore P BhatrajuDepartment of Medicine, Division of General Internal Medicine, University of Washington/Harborview Medical Center, 325 9Th Avenue, Box 359780, Seattle, WA, 98104, USA. epb6@uw.edu.
Devin N KennedyDepartment of Medicine, Division of General Internal Medicine, University of Washington/Harborview Medical Center, 325 9Th Avenue, Box 359780, Seattle, WA, 98104, USA.
Alexander J GojicDepartment of Medicine, Division of General Internal Medicine, University of Washington/Harborview Medical Center, 325 9Th Avenue, Box 359780, Seattle, WA, 98104, USA.
Matthew Iles-ShihDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA.
Joseph O MerrillDepartment of Medicine, Division of General Internal Medicine, University of Washington/Harborview Medical Center, 325 9Th Avenue, Box 359780, Seattle, WA, 98104, USA.
Jeffrey H SametClinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USA.
Kevin A HallgrenDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA.
Judith I TsuiDepartment of Medicine, Division of General Internal Medicine, University of Washington/Harborview Medical Center, 325 9Th Avenue, Box 359780, Seattle, WA, 98104, USA.

Funding

Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
NCCIH Supplement to NCATS/CTSA Program for KL2 Scholars - M. SoddersKL2TR002317 · NCATS · UNIVERSITY OF WASHINGTON · PI Christy Michelle McKinney · 2017 to 2026
$14.5M
NRSA Training CoreTL1TR002318 · NCATS · UNIVERSITY OF WASHINGTON · PI Megan Moore · 2017 to 2026
$8.4M
Patient Navigator plus Remote mHealth Adherence Support with Incentives: Understanding Criminal Justice EffectsR34DA057609 · NIDA · UNIVERSITY OF WASHINGTON · PI TSUI, JUDITH · 2022 to 2023
$842k
Building and Implementing Best Practices for Buprenorphine Initiation in the Setting of Fentanyl UseK23DA058751 · NIDA · UNIVERSITY OF WASHINGTON · PI Elenore Bhatraju · 2023 to 2026
$737k
NCATS NIH HHS KL2 TR002317NCATS NIH HHS TL1 TR002318NCATS NIH HHS UL1 TR002319NIDA NIH HHS 1R34DA057609-01NIDA NIH HHS 5K23DA058751-02NIDA NIH HHS K23 DA058751NIDA NIH HHS R34 DA057609
6 · The paper itself

Abstract

backgroundInitiation of buprenorphine for treatment of opioid use disorder (OUD) in acute care settings improves access and outcomes, however patients who use methamphetamine are less likely to link to ongoing treatment. We describe the intervention and design from a pilot randomized controlled trial of an intervention to increase linkage to and retention in outpatient buprenorphine services for patients with OUD and methamphetamine use who initiate buprenorphine in the hospital.

methodsThe study is a two-arm pilot randomized controlled trial (N = 40) comparing the mHealth Incentivized Adherence Plus Patient Navigation (MIAPP) intervention to treatment as usual. Development of the MIAPP intervention was guided by the information-motivation-behavioral skills model and combines financial rewards via mobile health-based adherence monitoring with the "human touch" of a patient navigator. Participants receive financial incentives for submitting videos of themselves taking buprenorphine via smartphone. The Patient Navigator reviews videos and provides treatment adherence coaching, care coordination and motivational enhancement. The intervention is introduced prior to hospital discharge and is offered for 30 days. The primary outcome is linkage to outpatient buprenorphine care within 30 days of hospital discharge. Secondary outcomes include retention on buprenorphine 90 days post discharge, hospital readmissions, and past 30-day methamphetamine use. DISCUSSION: Interventions are needed to increase linkage and retention to outpatient buprenorphine among hospitalized patients with OUD, especially for people who co-use methamphetamine. We will examine the MIAPP intervention to improve buprenorphine adherence and linkage to outpatient treatment in a pilot randomized controlled trial which will provide valuable insights about research approaches for hospitalized patients with substance use disorder. TRIAL REGISTRATION NUMBER: NCT06027814. Date of Initial Release: 08/30/2023. PROTOCOL VERSION: 03/21/2024.

Indexed as

Amphetamine-Related DisordersBuprenorphineMedication AdherenceNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPatient NavigationAdultFemaleHumansMaleMethamphetamineMotivationPilot ProjectsRandomized Controlled Trials as TopicTelemedicineBuprenorphineMethamphetamineNarcotic AntagonistsBuprenorphineMethamphetamine useMobile Health (mHealth)Opioid related disordersVideo directly observed therapy

Identifiers

PMID39881397
PMCPMC11780921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.